These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27589009)

  • 1. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
    Passot C; Mulleman D; Bejan-Angoulvant T; Aubourg A; Willot S; Lecomte T; Picon L; Goupille P; Paintaud G; Ternant D
    MAbs; 2016 Oct; 8(7):1407-1416. PubMed ID: 27589009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature.
    Fobelo Lozano MJ; Serrano Giménez R; Sánchez Fidalgo S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2264-2279. PubMed ID: 31315147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
    Ternant D; Pfister M; Le Tilly O; Mulleman D; Picon L; Willot S; Passot C; Bejan-Angoulvant T; Lecomte T; Paintaud G; Koch G
    Clin Pharmacokinet; 2022 Jan; 61(1):143-154. PubMed ID: 34351609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and use of infliximab.
    Klotz U; Teml A; Schwab M
    Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring.
    Barlow NL; Mohammed P; Berg JD
    Ann Clin Biochem; 2016 Jul; 53(Pt 4):477-84. PubMed ID: 26290514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
    Mori S
    Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
    Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
    J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
    Syversen SW; Goll GL; Jørgensen KK; Olsen IC; Sandanger Ø; Gehin JE; Warren DJ; Sexton J; Mørk C; Jahnsen J; Kvien TK; Bolstad N; Haavardsholm EA
    Trials; 2020 Jan; 21(1):13. PubMed ID: 31907007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection.
    Eser A; Reinisch W; Schreiber S; Ahmad T; Boulos S; Mould DR
    J Clin Pharmacol; 2021 Feb; 61(2):224-233. PubMed ID: 32905628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.
    Ternant D; Mulleman D; Lauféron F; Vignault C; Ducourau E; Wendling D; Goupille P; Paintaud G
    Br J Clin Pharmacol; 2012 Jan; 73(1):55-65. PubMed ID: 21692827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.